Predictive Oncology Reports First Quarter Financial Results

Rhea-AI Summary

Predictive Oncology (NASDAQ: POAI) reported Q1 2022 revenue of $314,568, up from $280,317 in Q1 2021, driven by a 6% increase in the Skyline segment and initial sales from zPREDICTA. The company reduced its loss per share to $0.05 from $0.11 year-over-year. Cash and equivalents stood at $25 million with no long-term debt. While general and administrative expenses decreased to $2.4 million, operating expenses rose due to zPREDICTA's staffing. The gross profit margin remained steady at 65%. The firm is optimistic about its commercialization efforts for Helomics and zPREDICTA.

Positive

• Revenue increased by 12% year-over-year.
• Loss per share improved to $0.05, down from $0.11.
• Cash and equivalents totaled $25 million with no long-term debt.
• General and administrative expenses decreased to $2.4 million.

Negative

• Operating expenses increased by $316,259 to $891,071.
• Sales and marketing expenses rose by $189,826 to $304,467.

EAGAN, Minn., May 12, 2022 (GLOBE NEWSWIRE) -- The financial results from the first quarter we believe depicts a solid potential for growth in the upcoming period, in accordance with the report by Predictive Oncology Inc. (NASDAQ: POAI) today, disclosing the results for the quarter ended March 31, 2022. The consolidated results of Predictive Oncology’s reportable segments included recognized revenue of $314,568 for the quarter.

The artificial intelligence (AI) and data-driven discovery services entity also reported an update on its business operations. Highlights from the quarter included:

• Discovery 21 and PeDAL® platform validated as Predictive Oncology moves ahead with commercialization.
• Cash and equivalents were $25 million as of March 31, 2022.
• The company has not reported any long-term debt obligations in its capital structure.
• Predictive Oncology’s reported loss per common share was reduced to $0.05, as compared to $0.11 for the comparable period in 2021.

“We are extremely excited that our technology provides a significant competitive advantage to our business offerings. Our CRO services business applies PeDAL to address a range of needs from discovery through clinical and translational research, to clinical trials and diagnostic development and validation. We believe this market segment has significant growth potential for Predictive Oncology and we believe we are differentiated from traditional CRO’s and other Artificial Intelligence companies through this unique asset,” said J. Melville Engle, the Company’s Chairman and Chief Executive Officer.

Q1 2022 Financial results

Predictive Oncology reported consolidated revenue of $314,568 for the quarter, as compared to $280,317 for the same quarter in 2021. The positive change was mainly due to an increase of 6% in the Skyline segment (STREAMWAY® System product sales) and initial revenue from the zPREDICTA segment.

The new zPREDICTA segment has an encouraging sales pipeline, including additional revenue from current transactions that are expected to be recognized in the next several quarters.

General and administrative expenses decreased from $3.3 million on March 31, 2021, to $2.4 million in on March 31, 2022. This represents a positive change between quarters resulting from decreased retirement, legal and other professional expenses.

The gross profit margin remained steady at approximately 65% for March 31, 2022, and March 2021, respectively.

Operations expense increased by $316,259 to $891,071 in the three months ended March 31, 2022, as compared to the comparable quarter of 2021, mainly due to higher costs related to staff from our zPREDICTA division acquired in late 2021.

Net cash used in operating activities was $3,093,696 and $3,322,091 for the three months ended March 31, 2022, and March 31, 2021, respectively. Cash used in operating activities decreased in March 2022 as compared to the comparable period of 2021, because of the decrease in cash used for working capital and lower operating costs.

The quarterly sales and marketing expenses of the company have increased by $189,826 for the quarter to $304,467, as compared to the comparable period in 2021. This increment was principally a direct result of the strategic decision to focus on the company’s commercialization efforts in 2022, which will be largely focused on the Helomics and zPREDICTA products. These factors increased the company’s expenses for corporate development, sales staff, marketing and public relations.

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through four segments (Skyline, Helomics, zPREDICTA and Soluble), which covers five subsidiaries: Helomics, TumorGenesis, Skyline Medical, zPREDICTA and Soluble Biotech.

TumorGenesis is the company’s arm for research and development for zPREDICTA, Soluble Biotech and Helomics. This subsidiary is also involved in media which aid cancer cells grow outside the body of patients and preserve their proteomic and RNA/DNA signatures. Helomics Holding Corporation is involved in applying artificial intelligence (“AI”) in the company’s precision medicine business, to offer AI-driven predictive models of tumor drug response to enhance clinical results for patients and to aid diagnostic, biotech and pharmaceutical industries in the new personalized diagnostics and drugs development. Skyline Medical Inc. (“Skyline Medical”), the STREAMWAY System is a fully automated wall-mounted system, which is utilized to dispose of an unlimited quantity of suction fluid offering continuous performance for medical practitioners while effectively eradicating healthcare professional’s exposure to potentially infectious liquids gathered during surgical and other medical operations. Soluble Biotech Inc. is involved in research focused on protein production, stability studies and solubility improvements. zPREDICTA, Inc carries out tumor-specific research using vitro models for oncology and drug development.

Forward-Looking Statements:
This press release comprises of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management's beliefs and certain assumptions made by our management. Words such as "expects," "plans," "intends," "anticipates," "believes," "estimates," "seeks," variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). The Company’s actual results may differ materially from the anticipated results reflected in these forward-looking statements.

PREDICTIVE ONCOLOGY INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

		March 31, 2022					December 31, 2021
		(unaudited)					(audited)
ASSETS
Current Assets:
Cash and Cash Equivalents		$	25,115,561				$		28,202,615
Accounts Receivable			264,966						354,196
Inventories			455,680						387,684
Prepaid Expense and Other Assets			408,102						513,778
Total Current Assets			26,244,309						29,458,273
Fixed Assets, net			2,335,692						2,511,571
Intangibles, net			3,893,438						3,962,118
Lease Right-of-Use Assets			651,921						814,454
Other Long-Term Assets			75,618						167,065
Goodwill			6,857,790						6,857,790
Total Assets		$	40,058,768				$		43,771,271
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts Payable		$	1,106,811				$		1,021,774
Accrued Expenses and other liabilities			695,416						1,262,641
Derivative Liability			127,572						129,480
Deferred Revenue			182,626						186,951
Lease Liability			568,825						639,662
Total Current Liabilities			2,681,250						3,240,508
Lease Liability – Net of current portion			133,926						239,664
Other long-term liabilities			63,098						25,415
Total Liabilities			2,878,274						3,505,587
Stockholders’ Equity:
Preferred Stock, 20,000,000 authorized inclusive of designated below
Series B Convertible Preferred Stock, $.01 par value, 2,300,000 shares authorized, 79,246 shares outstanding			792						792
Common Stock, $.01 par value, 200,000,000 shares authorized, 65,906,465 and 65,614,597 outstanding			659,065						656,146
Additional paid-in capital			167,931,634						167,649,028
Accumulated Deficit			(131,410,997	)					(128,040,282	)
Total Stockholders’ Equity			37,180,494						40,265,684
Total Liabilities and Stockholders’ Equity		$	40,058,768					$	43,771,271

PREDICTIVE ONCOLOGY INC.
CONDENSED CONSOLIDATED STATEMENTS OF NET LOSS
(Unaudited) 

		Three Months Ended March 31,
		2022				2021
Revenue		$	314,568			$	280,317
Cost of goods sold			109,443				97,758
Gross margin			205,125				182,559
General and administrative expense			2,423,651				3,270,777
Operations expense			891,071				574,812
Sales and marketing expense			304,467				114,641
Total operating loss			(3,414,064	)			(3,777,671	)
Other income			42,430				28,259
Other expense			(989	)			(234,972	)
Gain on derivative instruments			1,908				95,671
Net loss		$	(3,370,715	)		$	(3,888,713	)
Loss per common share - basic and diluted		$	(0.05	)		$	(0.11	)
Weighted average shares used in computation - basic and diluted			65,835,080				36,513,300

Investor Relations Contact:

Landon Capital
Keith Pinder
(404) 995-6671
kpinder@landoncapital.net

FAQ

What are the Q1 2022 financial results for Predictive Oncology (POAI)?

Predictive Oncology reported a Q1 2022 revenue of $314,568, an increase from $280,317 in Q1 2021.

How much did Predictive Oncology (POAI) improve its loss per share in Q1 2022?

The loss per share improved to $0.05 in Q1 2022, down from $0.11 in the same period last year.

What is the current cash position of Predictive Oncology (POAI)?

As of March 31, 2022, Predictive Oncology had cash and equivalents of $25 million.

What factors contributed to the revenue growth of Predictive Oncology (POAI) in Q1 2022?

The revenue growth was primarily driven by a 6% increase in the Skyline segment and initial revenues from the zPREDICTA segment.

What changes occurred in the expenses of Predictive Oncology (POAI) for Q1 2022?

General and administrative expenses decreased to $2.4 million, while operating expenses increased due to heightened costs from staffing for the zPREDICTA division.